Infectious Disease Clinics of North America volume 25, issue 4, P789-802 2011 DOI: 10.1016/j.idc.2011.07.006 View full text
|
|
Share
Jan ter Meulen

Abstract: Of the more than 20 monoclonal antibodies (mAbs) generated to combat infectious diseases (ID) that are in clinical development in 2011, most are in phase 1 or 2 and are directed against either viruses or bacterial toxins. Several high-profile anti-ID mAbs have recently failed in clinical trials. Despite the advancement in recombinant engineering technologies, anti-ID mAbs have yet to deliver on their promise as "magic bullets," especially against nosocomial infections. A paradigm shift in favor of developing m…

expand abstract